Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Nuclear receptors: emerging drug targets for parasitic diseases
Zhu Wang, … , Steven A. Kliewer, David J. Mangelsdorf
Zhu Wang, … , Steven A. Kliewer, David J. Mangelsdorf
Published April 3, 2017; First published February 6, 2017
Citation Information: J Clin Invest. 2017;127(4):1165-1171. https://doi.org/10.1172/JCI88890.
View: Text | PDF
Category: Review Series

Nuclear receptors: emerging drug targets for parasitic diseases

  • Text
  • PDF
Abstract

Parasitic worms infect billions of people worldwide. Current treatments rely on a small group of drugs that have been used for decades. A shortcoming of these drugs is their inability to target the intractable infectious stage of the parasite. As well-known therapeutic targets in mammals, nuclear receptors have begun to be studied in parasitic worms, where they are widely distributed and play key roles in governing metabolic and developmental transcriptional networks. One such nuclear receptor is DAF-12, which is required for normal nematode development, including the all-important infectious stage. Here we review the emerging literature that implicates DAF-12 and potentially other nuclear receptors as novel anthelmintic targets.

Authors

Zhu Wang, Nathaniel E. Schaffer, Steven A. Kliewer, David J. Mangelsdorf

×

Figure 1

The DAF-12 signaling pathway.

Options: View larger image (or click on image) Download as PowerPoint
The DAF-12 signaling pathway.
(A) Under favorable environmental conditio...
(A) Under favorable environmental conditions, the free-living nematode C. elegans stimulates the production of steroid-like hormones (i.e., DAs) that activate the DAF-12 nuclear receptor. DAF-12 activation results in transcription of a metabolic and development gene network that promotes reproductive maturity. (B) In unfavorable conditions when DAs are not synthesized, DAF-12 functions as a transcriptional repressor of this gene network that results in developmental arrest and entry into the dauer diapause. In helminthic nematodes, this same pathway is believed to govern the development of infectious larvae and the resumption of their development into reproductive maturity after entering their hosts.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts